Bruce J. Trock, Ph.D.

Director, Division of Epidemiology, Brady Urological Institute at Johns Hopkins
Frank Hinman, Jr. Professor of Urology
Professor of Epidemiology
Professor of Oncology
Johns Hopkins Medical Institutions

600 N. Wolfe St. , 211 Park Bldg. , Baltimore, MD 21287-8915

Appointments: 410-955-2517

Office: 410-614-9440


Fax: 410-502-7711

BDr. Bruce Jeffrey Trock is the Frank Hinman Jr. endowed Professor of Urology, and is Professor of Epidemiology and Oncology at the Johns Hopkins School of Medicine. He serves as the Director of the Division of Epidemiology in the Brady Urological Institute at Johns Hopkins. His research focuses on prostate cancer.  Prior to joining Johns Hopkins, Dr. Trock was a tenured associate professor at Georgetown University’s Lombardi Cancer Center, where he was also Director of the Cancer Biomarker Resource, with prior positions at the Fox Chase Cancer Center, and the University of Pennsylvania.

In addition to his faculty appointments at Johns Hopkins, Dr. Trock is the Director of the Biostatistics Core for the Johns Hopkins Specialized Program of Research Excellence (SPORE) in Prostate Cancer.  He also was the founding Director, and is now Co-Director of the Prostate Cancer Biorepository Network, a collaboration between the Johns Hopkins University School of Medicine, the New York University School of Medicine, University of Washington, the Institute of Cancer Research (London), Washington University,  and the United States Department of Defense that provides high quality, well-annotated prostate cancer tissues and biospecimens to prostate cancer researchers worldwide.
Dr. Trock has authored or co-authored more than 270 published articles and has been principal or co-principal investigator on numerous research grants.


September 1986 Johns Hopkins University School of Hygiene
Baltimore, MD
Doctor of Philosophy, Epidemiology
Chairman: Leon Gordis, M.D.
June 1979 University of Michigan School of Public Health
Ann Arbor, MI
Master of Public Health, Epidemiology
June 1976

Michigan State University
East Lansing, MI
Bachelor of Science, Physiology

August 1974 University of Michigan -Ann Arbor, MI
Bachelor of Science, Mathematics




   Free Access to abstracts at PubMed

  1. Lawrence CE, Taylor PR, Trock BJ, Reilly AA: Trihalomethanes in drinking water and human colorectal cancer.  J Nat Cancer Inst 72(3): 563-568, 1984.

  2. Weed DL, Trock BJ: Criticism and the growth of epidemiologic knowledge.  (Letter)  AmerJ of Epidemiol 123(6): 1119-1120, 1986.

  3.  Weed DL, Trock BJ: Interactions and public health decisions.  J Clin Epi 41: 207-209, 1988.

  4.   Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, et al. A model predicting survival in Stage I melanoma based upon tumor progression and multivariable logistic regression.  JNCI 81: 1893-1904, 1989.

  5.  King E, Rimer BK, Trock B, Balshem A, Engstrom P: How valid are mammography self-reports?  Amer J of Public Health 80(11): 1386-1388, 1990.

  6.  NCI Breast Cancer Screening Consortium.  Screening mammography:  A missed clinical opportunity.  JAMA 264: 54-58, 1990.

  7.  Lerman C, Rimer B, Trock B, et al. Factors associated with repeat adherence to breast cancer screening.  Prev Med 19: 279-290, 1990.

  8.  Myers RE, Trock BJ, Lerman C, et al.Adherence to colorectal screening in an HMO population.  Prev Med 19: 502-514, 1990.

  9.  Rimer BK, Trock BJ, et al.  Breast screening practices among primary physicians:  Reality and potential.  J Amer Board of Family Practice 3: 26-34, 1990.

  10.  Rimer BK, Trock BJ:  Letter to the Editor.  J Amer Board of Family Practice 3: 140-1, 1990.

  11.  Rosenthal SA, Trock BJ, Coia LR: Randomized trials of adjuvant radiation therapy for rectal carcinoma:  A Review.  Dis of  Colon and Rectum 33: 335-343, 1990.

  12.  Corn BW, Trock BJ, Goodman RL: Radiation-related ischemic heart disease.  J Clin Oncol 8: 1-10, 1990.

  13. Trock BJ, Lanza E, Greenwald P: High fiber diet and colon cancer: A critical review.  Prog Clin Biol Res 346: 145-157, 1990.

  14. Trock BJ, Lanza E, Greenwald P: Dietary fiber, vegetables, and colon cancer: Critical review and meta-analysis of the epidemiologic evidence.  J Nat Cancer Inst 82: 650-661, 1990.

  15.  Lerman C, Trock B, Rimer B, et al. Psychological and behavioral implications of abnormal mammograms.  Ann Intern Med 114: 657-661, 1991.

  16.  Lerman C, Trock B, Rimer B, et al.  Psychological side effects of breast cancer screening.  Health Psychol 1991; 10:259-267.

  17.  Coughlin SS, Nass CC, Pickle LW, Trock B, Bunin G: Regression methods for estimating attributable risk in population-based case-control studies:  A comparison of additive and multiplicative models.  Amer J Epidemiol 133: 305-313, 1991.

  18.  Rimer BK, Trock B, Engstrom PF, Lerman C, King E: Why do some women get regular mammograms?  Am J Prev Med 7(2): 69-74, 1991.

  19. Trock BJ:  Biological markers as predictors of risk in aerodigestive tract cancers.  Adv Exp Med Biol 1992; 320:47-54.

  20. Coughlin SS, Trock B, Criqui MH, et al.  The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test.  J Clin Epidemiol 45: 1-7, 1992.

  21.  Coughlin SS, Trock B, Criqui MH, et al. Response:  Dr. Diamond’s clinical epistemology of sensitivity and specificity.  J Clin Epidemiol 1992; 45:15-16.

  22. Halpern AC, Guerry D, Elder DE, Trock B, et al. Natural history of dysplastic nevi. J Amer Acad Derm 29:51-57, 1993.

  23.  Halpern AC, Guerry D, Elder DE, Trock B, Synnestvedt M: A cohort study of melanoma in patients with dysplastic nevi.  J Invest Derm 100:346S-349S, 1993.

  24. Trock BJ, Rimer BK, King E, et al. Impact of an HMO-based intervention to increase mammography utilization.  Cancer Epidemiol Biomark Prev 2:151-156, 1993.

  25. Buchert ET, Woosley RL, Swain SM, Oliver SJ, Coughlin SS, Pickle L, Trock B, et al.  Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility.  Pharmacogenetics 1993; 3:322-327.

  26. Halpern AC, Schuchter LM, Elder DE, Guerry D, Elenitsas R, Trock B, Matozzo I.  The effects of topical tretinoin on dysplastic nevi.  J Clin Oncol 1994; 12:1028-1035.

  27. Sauter ER, Cleveland D, Trock B, et al.  p53 is overexpressed in fifty percent of pre‑invasive lesions of head and neck epithelium.  Carcinogenesis 1994;15:2269‑2274.
  28. Corn BW, Trock BJ, Curran WJ.  Management of primary CNS lymphoma in the AIDS patient: Confronting a clinical Catch-22.  Cancer 1995; 76:163-166.

  29. Silverman PM, Cooper C, Trock B, et al.  The optimal temporal window for CT of the liver using a time‑density analysis: implications for helical (spiral) CT.   J Comput Assist Tomogr 1995; 19(1):73‑79.

  30.  Trock BJ.  Application of biomarkers in cancer environmental epidemiology.  Toxicology 1995; 101:93-98.

  31.  Atienza DM, Vogel CL, Trock BJ, Swain SM.  Phase II study of oral etoposide in patients with advanced breast cancer.   Cancer 1995; 76:2485-2490.

  32. Singh AD, Shields CL, De Potter P, Shields JA, Trock B, et al.  Familial uveal melanoma: clinical observations on 56 cases.  Arch Opthalmol 1996; 114:392-399.

  33.  Sauter ER, Ridge JA, Trock B, et al.  p53 overexpression in primary and metastatic head and neck carcinomas.  Laryngoscope 1995; 105:653-656.

  34.  Trock BJ.  Breast cancer in African American women: epidemiology and tumor biology.  Breast Cancer Res Treat 1996; 40:11-24.

  35.  Dickson RB, Low JA, Johnson MD, Hawkins MJ, Trock BJ.  Blood-borne indicators of breast cancer and their use in experimental, medical oncologic, and prevention studies.  The Breast 1996; 5:379-384.

  36. McLeskey SW, Zhang L, Karbanda S, Liu Y, Trock BJ, et al.  Effects of AGM-1470 and pentosan polysulfate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells.  Br J Cancer 1996; 73:1053-1062.

  37.  Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, et al.  A prognostic model to predict ten-year survival in patients with primary melanoma.  Ann Intern Med 1996; 125:369-375.

  38.  Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, et al.  BRCA1 testing in families with hereditary breast-ovarian cancer:  a prospective study of patient decision-making and outcomes.  JAMA  1996; 275:1885-1892.

  39. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, et al.  Immunohistochemical staining for glutathione S-transferase predicts response to platinum based chemotherapy in head and neck cancer.   Clinical Cancer Research 1996; 2:1859-1865.

  40. Trock BJ, Leonessa F, Clarke R.  Multidrug resistance in breast cancer A meta-analysis of MDR1/gp170 expression and its possible functional significance.  J Natl Cancer Inst 1997; 89:917-931.

  41. McLeskey SW, Zhang L, El Ashry D, Trock BJ, Lopez CA, et al.  Tamoxifen-resistant FGF-transfected MCF-7 cells are cross resistant in vivo to the antiestrogen, ICI 182,780, and two aromatase inhibitors.  Clin Cancer Res 1998; 4:697-711.

  42.  Gandour-Edwards R, Trock BJ, Gumerlock P, et al.  Heat shock protein and p53 expression in head and neck squamous cell carcinoma.   Otolaryngol Head Neck Surg 1998; 118:610‑5

  43.  Giani C, Pinchera A, Rasmussen A, Fierabracci P, Bonacci R, Campini D, Bevilacqua G, Trock B, Lippman ME, Cullen KJ.  Stromal IGF‑II messenger RNA in breast cancer: relationship with progesterone receptor expressed by malignant epithelial cells. J Endocrinol Invest 1998; 213:160‑5.

  44. Brankin B, Skaar TC, Brotzman M, Trock B, Clarke R.  Autoantibodies to the nucleolar phosphoprotein nucleophosmin in breast cancer patients.   Cancer Epidemiol Biomark Prev  1998; 7:1109-1115.

  45.  Hayes DF, Trock B, Harris AL.  Assessing the clinical impact of prognostic factors:  when is “statistically significant” clinically useful.  Breast Cancer Res Treat 1998;52:305‑19.

  46. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, et al.  Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer.  Chem Biol Interact 1998; 111-112:187-198.

  47.  Lawrence WF, Liang W, Mandelblatt JS, Gold KF, Freedman M, Ascher SM, Trock BJ, Chang P  Serendipity in diagnostic imaging: magnetic resonance imaging of the breast.  J Natl Cancer Inst 1998;90:1792‑800.

  48. Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, Abbaszadegan MR, Harty AE, Franklin BA, Lynch JF, Lynch HT.  Genetic testing in families with hereditary nonpolyposis colon cancer.  JAMA 1999;281:1618‑22.

  49.  Gandour-Edwards R, Trock B, Donald PJ.  Predictive value of cathepsin-D for cervical lymph node metastasis in head and neck squamous cell carcinoma.  Head Neck 1999; 21:718-722.

  50. Shiga H, Heath EI, Rasmussen A, Trock B, Johnston PG, et al.   Prognostic value of p53, glutathione s-transferase p, and thymidylate synthase for neoadjuvant cisplatin- based chemotherapy in head and neck cancer.  Clin Cancer Res 1999; 5:4097-4104.

  51. Trock BJ.  Out of the mouths of babes : Oral premalignant lesions and alternative tobacco products.  Cancer Epidemiol Biomarkers Prev 2000; 9:637-638 (invited editorial).

  52. Deming SL, Nass SJ, Dickson RB, Trock BJ.  C-myc amplification in breast cancer:  a meta-analysis of its occurrence and prognostic relevance.  Br J Cancer 2000; 83:1688-95.

  53. Beebe KL, Zaninelli R, Trock B.  Re: "antidepressant medication use and breast cancer risk (letter).  Am J Epidemiol 2000;152:1104-5.

  54. Clarke R, Hilakivi-Clarke L, Trock B.  Breast cancer:  Dietary and environmental oestrogens.  Biologist 2001; 48:21-26.

  55. Trock BJ.  Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.  Urology 2001; 57(4 Suppl 1):241-7.

  56. Davidson BJ, Root WA, Trock BJ.   Age and survival from squamous cell carcinoma of the oral tongue.  Head and Neck 2001; 23:273-279.

  57. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF 3rd.  New approaches to proteomic analysis of breast cancer.  Proteomics 2001;1:1205-15.

  58. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?  Urology 2001;58:746-51.

  59.  Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF 3rd.  Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer.  Dis Markers 2001;17(4):301-7.
  60.  Gonzalgo ML, Eisenberger CF, Lee SM, Trock BJ, Marshall FF, Hortopan S, Sidransky D,   Schoenberg MP. Prognostic significance of preoperative of molecular serum analysis   renal cancer.  Clin Cancer Res 2002; 8(6):1878-81

  61. Gretzer MB, Trock BJ, Han M, Walsh PC.  A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology (ASTRO) criteria.  J Urol 2002; 68:1419-1422.

  62.  Zhou A, Megnekou R, Leke R, Fogako J, Metenou S, Trock B, Taylor DW, Leke RF.  Prevalence of Plasmodium falciparum infection in pregnant Cameroonian women.  Am J Trop Med Hyg 2002; 67(6):566-70.

  63.  Hsu TH, Su LM, Ratner LE, Trock BJ, Kavoussi LR.  Impact of renal artery multiplicity on outcomes of renal donors and recipients in laparoscopic donor nephrectomy.  Urology 2003; 61(2):323-7.

  64.  Hsu TH, Su LM, Trock BJ, Ratner LE, Colombani P, Kavoussi LR.  Laparoscopic adult donor nephrectomy for pediatric renal transplantation.  Urology 2003; 61(2):320-2.

  65.  Wood HP, Trock BJ, Gearhart JP.  In vitro fertilization and cloacal-bladder extrophy-epispadias complex:  Is there association?  J Urol 2003;169:1512-5.

  66. Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP.  Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003; 170(2 Pt 1):503-6.

  67. Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, ClarkeR, Sholler PF, Lirio AA, Foss C, Reiter R, Trock B, Paik S, Martin MB.   Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland.  Nat Med 2003; 9:1081-4.

  68.  Liang W, Lawrence WF, Burnett CB, Hwang YT, Freedman M, Trock BJ, Mandelblatt JS,Lippman ME.  Acceptability of diagnostic tests for breast cancer.  Breast Cancer Res Treat 2003; 79:199-206.

  69. Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR, Blute ML, Roehrborn CG, Partin AW.  Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.  Urology 2004; 63:716-21.

  70. Freedland SJ, Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, Kane CJ.  Predictors of PSA progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004; 100:1633-8.

  71. Varkarakis JM, McAllister M, Ong AM, Solomon SB, Allaf ME, Inagaki T, Bhayani SB, Trock B, Jarrett TW.   Evaluation of water jet morcellation as an alternative to hand morcellation of renal tissue ablation during laparoscopic nephrectomy: an in vitro study.  Urology 2004; 63:796-9.

  72. Rogers CG, Trock B, Walsh PC.  Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results.  Urology 2004; 64:148-51.

  73.   Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ.  Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.  J Urol 2004; 172:520-4.

  74. Su LM, Ratner LE, Montgomery RA, Jarrett TW, Trock BJ, Sinkov V, Bluebond-Langner R, Kavoussi LR.  Laparoscopic Live Donor Nephrectomy: Trends in donor and recipient morbidity following 381 consecutive cases.  Ann Surg 2004; 240:358-363.

  75. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr, Trock B, Amling CL.   Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.  Cancer 2004; 101:748-753.

  76.  Bhayani SB, Rha KH, Pinto PA, Ong AM, Allaf ME, Trock BJ, Jarrett TW, Kavoussi LR. Laparoscopic partial nephrectomy:  effect of warm ischemia on serum creatinine.  J Urol 2004; 172:1264-1266.

  77. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC.  Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long- term follow-up.   J Urol 2004; 172:1860-4.

  78. Allaf ME, Palapattu GS, Trock BJ, Epstein JI, Walsh PC.  Anatomical extent of lymph node dissection at the time of radical prostatectomy: impact on PSA progression.  J Urol 2004; 172:1840-4.

  79. Palapattu GS, Haisfield-Wolf ME, Walker JM, Brintzenhofeszoc K, Trock BJ, Zabora J, Schoenberg M.  Assessment of peri-operative psychological distress in patients undergoing radical cystectomy for bladder cancer.  J Urol 2004; 172:1814-7.

  80. Palapattu GS,  Bastian PJ, Slavney PR, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J, Schoenberg M.  Pre-operative somatic complaints are associated with disease progression in patients with bladder cancer following cystectomy.  Cancer 2004; 101:2209-13.

  81. Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC.  Radical retropubic prostatectomy:  how often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173:446-9.

  82.    Stearns V, Coop A,  Singh B, Gallagher A, Yamauchi Y, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ.A pilot surrogate endpoint biomarker trial of perillyl alcohol (POH) in breast neoplasia.  Clin Cancer Res 2004; 10:7583-7591.

  83.  Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R,             Brown M, Cullen J, Trock B, Hayes DF.  A pilot study to establish a clinical model to        perform phase II studies of breast cancer chemopreventive agents in women at high risk   with biomarkers as surrogate endpoints for activity. Clin Cancer Res 2004; 10:8332-8340.

  84.  Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.  J Urol 2005; 173:450-3.

  85.  Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF 3rd, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. < Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.  J Clin Invest 2005; 115:1163-76.

  86.  Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.  J Clin Oncol. 2005; 23:3614-21.

  87.  Ellison LM, Trock BJ, Poe NR, Partin AW. The effect of hospital volume on cancer control after radical prostatectomy.  J Urol 2005;173:2094-8.

  88.   Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11:4037-43.

  89.   Gonzalgo ML, Pavlovich CP, Trock BJ, Link RE, Sullivan W, Su LM.  Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy. J Urol 2005; 174:135-9.

  90.   Trock B.  Invited editorial comment re:  Screening with prostate specific antigen and        metastatic prostate cancer risk:  a population based case-control study.  J Urol 2005;             174:499.

  91.   Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK.  Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy.  Clin Cancer Res 2005; 11:7735-42.

  92.   Clarke R, Leonessa F, Trock B.  Multidrug resistance/p-glycoprotein and breast cancer:  review and meta-analysis.  Seminars in Oncol 2005; 32(6 Suppl 7):S9-15.

  93.   Rais-Bahrami S, Lima GC, Varkarakis IM, Romero FR, Trock B, Jarrett TW, Kavoussi LR.  Intraoperative conversion of laparoscopic partial nephrectomy.  J Endourol 2006; 20:205-8.

  94.   Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome.  J Natl Cancer Inst 2006;  98:355-7.

  95.  Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin    AW.  Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of        the prostate.  Urology 2006; 67:115-9.

  96.  Trock B, Clarke R,  Hilakivi-Clarke L.  Meta-analysis of soy intake and breast cancer risk.  J Natl Cancer Inst 2006; 98:459-471.

    97.       Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovic C, Jankowiak R.  Potential biomarker for early risk assessment of prostate cancer.  The Prostate 2006; 66:1565-1571.

  97.    Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer   chemoprevention.  J Clin Oncol 2006; 24:2128-9.

  98.   Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of life-threatening prostate cancer with PSA velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521-1527.

  99.      Carter HB, Ferrucci L, Kettermann A, Landis P, Wright J, Epstein JI, Trock BJ, Metter EJ.                Response:  Re: Detection of life-threatening prostate cancer with prostate-specific antigen        velocity during a window of curability (letter).  J Natl Cancer Inst 2007; 99:490.
  100.   Parsons JK, Partin AW, Trock B, Bruzek DJ, Cheli C, Sokoll LJ.  Complexed prostate- specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy.          BJU Int 2007; 99:758-61.

  101.  Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given PSA, clinical       stage, and biopsy Gleason score (Partin tables) based on cases from 2000-2005. Urology     2007;   69:1095-1101.

  102.   Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock BJ, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.  Clin Cancer Res 2007; 13:5361-5367.

  103.   Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, et al.  Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.  J Urol 2007; 178:1311-1315

  104.   Romero FR, Schaeffer EM, Muntener M, Trock BJ, Kavoussi LR, Jarrett TW.  Oncologic outcomes of extravesical stapling of distal ureter in laparoscopic nephroureterectomy.  J Endourol 2007; 21:1025-1028.

  105.   Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, et al.  Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.  J Natl Cancer Inst 2007; 1525-1533.

  106.    Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.  Impact of patient age on biochemical recurrence rates following radical prostatectomy.  J Urol 2007; 178:1933-1937.

  107.   Wagner AA, Link RE, Trock BJ, Sullivan W, Pavlovich CP. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon’s early experience.  Urology 2007; 70:667-671. 

  108.   Nielsen ME, Bastian PJ, Palapattu GS, Trock BJ, Schoenberg MP, Chan T, Rogers CG.  Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.  Urology 2007; 70:1091-1095. 

  109.    Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.  J Natl Cancer Inst 2007; 99:1836-1844. 

  110.     Semins MJ, Trock BJ, Matlaga BR.  The effect of shock wave rate on the outcome of shock-wave lithotripsy: a meta-analysis.  J Urol 2008; 179:194-197; discussion 197. 

  111.    Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA,     Walsh PC, Trock BJ.  The natural history of men managed with deferred androgen deprivation therapy who developed metastatic prostate cancer following radical    prostatectomy.  J Urol 2008; 179:156-161; discussion 161-162.

  112.     Hoque MH, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow K, Rosenbaum E, Trock BJ, Westra WH, Schoenberg M, Goodman SN, Sidransky D.  TIMP3 promoter methylation     is an independent prognostic factor for bladder cancer.  J Urol 2008; 179(2):743-7.

  113.      Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG.  CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.  J Urol 2008; 179(2):529-34; discussion 534-5.

  114.      Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM.  3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.  J Urol 2008; 179(3):917-21; discussion  921-2.

  115.       Landefeld CS, Bowers BJ, Feld AD, Hartmann KE, Hoffman E, Ingber MJ, King JT Jr, McDougal WS, Nelson H, Orav EJ, Pignone M, Richardson LH, Rohrbaugh RM, Siebens HC, Trock BJ.  National Institutes of Health State-of-the-Science Statement: Prevention of fecal and urinary incontinence in adults.  Ann Intern Med 2008; 148(6):449-58.  

  116.     Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.  Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol 2008; 179(5):1780-4; discussion 1784.

  117.       Makarov DV, Trock BJ, Allaf ME, Matlaga BR.  The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis.  Urology 2008; 71(5):796-800.

  118.       Trock BJ.  Seminar section introduction: A clinician’s guide to statistical methods in urologic oncology. Urol Oncol 2008; 26(3):299.   

  119.  Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, et al.       Differential effects of leptin on the invasive potential of androgen-dependent and         independent prostate carcinoma cells.  J Biomed Biotechnol 2008; 2008(163902): 1-8.

  120. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI.  Natural history of pathologically organ-confined (pT2), gleason score 6 or less, prostate cancer after radical prostatectomy.  Urology 2008; 72(1):172-6.   

  121. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC.    Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with           biochemical recurrence after radical prostatectomy:  JAMA 2008; 299(23):2760-9. 

  122.   Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD,      Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL.  Cumulative        effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008; 68(12):1257-62. 

  123. Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y,             Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Adolfsson J,             Johansson JE, Lowey J, Trock BJ, Partin AW, et al.  Evidence of two independent prostate             cancer risk-associated loci in HNF1B gene at 17q12.  Nat Genet 2008; 40(10):1153-5. 

  124.  Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu , Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Grönberg H, Isaacs W, Zheng S.  Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008; 14(18):5819-24. 

  125.   Rais-Bahrami S, Romero FR, Lima GC, Kohanim S, Permpongkosol S, Trock BJ, Jarrett TW, Kavoussi LR.  Elective laparoscopic partial nephrectomy in patients with tumors >4 cm. Urology 2008; 72(3):580-3. 

  126.   Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008; 72(6):1246-51.

  127.   Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B.  Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in Type 2 diabetic men with erectile dysfunction.  J Urol 2009; 181(1):245-51.

  128.   Semins MJ, Trock BJ, Matlaga BR.  The safety of ureteroscopy during pregnancy: A Systematic review and meta-analysis.  J Urol 2009; 181:139-43.

  129.  Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly—when to stop? J Urol 2009; 181: 1606-14. 

  130.  Yang L, Gaikwad NW, Meza J, Cavalieri EL, Trock BJ, Rogan EG. Novel biomarkers for             risk of prostate cancer: Results from a case-control study. Prostate 2009; 69:41-8. 

  131.  Richstone L, Seideman CA, Reggio E, Bluebond-Langner R, Pinto PA, Trock B, Kavoussi LR.  Pathological findings in patients with ureteropelvic junction obstruction and crossing vessels.  Urology 2009; 73:716-9.  

  132.   Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, Demarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Issacs W.  Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009; 69:1195-1205.

  133.    Trock BJ, Guo CC, Gonzalgo ML, Maheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after radical prostatectomy: proposal for a modified Gleason scoring system. J Urol 2009; 182:1364-70.

  134.   Novak TE, Lakshmanan Y, Trock BJ, Gearhart JP, Matlaga BR.  Sex prevalence of pediatric kidney stone disease in the united states: an epidemiologic investigation. Urology 2009; 74:104-7.

  135.  Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Prestijr JC, Kane CJ, Amling CL, Moul JW, Freedland SJ.  Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol 2009; 182:491-6.

  136.  Zhou J, Trock B, Tsangaris TN, et al.   A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient.  Breast Cancer Res Treat. 2010; 123:73-86.

  137.   Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC.  What are the outcomes of radical prostatectomy for high-risk prostate cancer?  Urology 2010; 76:710-4.

  138.  Nielsen ME, Trock BJ, Walsh PC.  Salvage or adjuvant radiation therapy: counseling             patients on the benefits.  J Natl Compr Canc Netw 2010; 8:228-37.

  139.    Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB.  Risk stratification of men choosing surveillance for low risk prostate cancer.  J Urol 2010; 183:1779-85.

  140.  Trock BJ, Walsh PC.  Re:  Radiation therapy after radical prostatectomy: impact on metastasis and survival S. A. Boorjian, R. J. Karnes, P. L. Crispen, L. J. Rangel, E. J. Bergstralh and M. L. Blute J Urol 2009; 182: 2708-2715.  J Urol 2010; 183:2466-7;

  141.  Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S, Carter HB.  Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.  BJU Int. 2010; 106:1284-90.

  142.  Sidana A, Aggarwal P, Feng Z, Georgiades CS, Trock BJ, Rodriguez R.  Complications of renal cryoablation:  a single center experience.  J Urol 2010; 194:42-7.

  143.  Semins MJ, Trock BJ, Matlaga BR.  Validity of administrative coding in identifying patients with upper urinary tract calculi.  J Urol 2010; 184:190-2.

  144.   Han M, Trock BJ, Partin AW, Humphreys EB, Bivalacqua TJ, Guzzo TJ, Walsh PC.  The impact of preoperative erectile dysfunction on survival after radical prostatectomy.  BJU Int 2010; 106:1612-7.

  145.    Matlaga BR, Schaeffer AJ, Novak TE, Trock BJ.  Epidemiologic insights into pediatric kidney stone disease.  Urol Res 2010; 38:453-7.

  146.   Trock BJ, Walsh PC.  Re:  Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death (letter).  Cancer 2011; 117:656

  147.   Han M, Kim C, Mozer P, Schafer F, Badaan S, Vigaru B, Tseng K, Petrisor D, Trock B, Stoianovici D.  Tandem-robot assisted laparoscopic radical prostatectomy to improve the neurovascular bundle visualization:  a feasibility study.  Urology 2011; 77:502-6.

  148.   Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.  Predicting 15-year prostate cancer-specific mortality after radical prostatectomy.  J Urol 2011; 185:869-75.

  149.   Schaeffer AJ, Feng Z, Trock BJ, Mathews RI, Neu AM, Gearhart JP, Matlaga BR.  Medical comorbidities associated with pediatric kidney stone disease.  Urology 2011; 77:195-9.

  150.   Lin BM, Hyndman ME, Steele KE, Feng Z, Trock BJ, Schweitzer MA, Pavlovich CP.  Incidence and risk factors for inguinal and incisional hernia after laparoscopic radical prostatectomy.  Urology 2011; 77:957-62.

  151.   Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB.  Active surveillance for very low-risk prostate cancer: an update of the Johns Hopkins experience.  J Clin Oncol 2011; 29:2185-90.

  152.  Eifler JB, Levinson AW, Hyndman ME, Trock BJ, Pavlovich CP.  Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy.  J Urol 2011; 185:1661-5.

  153.   Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC.  Can we stop prostate- specific antigen testing 10 years after radical prostatectomy?  J Urol 2011; 186:500-5.

  154.  Karram S, Trock BJ, Netto GJ, Epstein JI.  Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy?  Correlation with radical prostatectomy findings.  Am J Surg Pathol 2011; 35:1351-5.

  155.  Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg R.  Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy.  J Transl Med 2011; 9:153.

  156.  Baradan N, Cervellione RM, Orosco R, Trock BJ, Costello J, Mathews R, Gearhart JP. The effect of a failed initial closure on bladder growth in children with bladder exstrophy. J Urol 2011; 186:1450-4.

  157.   Trock BJ.  Application of metabolomics to prostate cancer.  Urol Oncol 2011; 29:572-81.

  158.  Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, Mehrotra J, Raghavan B, Partin AW.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in high-risk men with negative initial prostate biopsies.  BJUI 2012; 110:56-62.

  159.   Loeb S, Trock BJ.  Re:  Randomised prostate cancer screening trial: 20 year follow-up. Sandblom G, Varenhors E, Rosell J, Lofman O, Carlsson P.  BMJ 2011;342:d1539.  Eur Urol 2011; 60:1306-7.

  160.   Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, Epstein JI.  Treatment decision-making for localized prostate cancer:  What younger men choose and why.  Prostate  2012; 72:58-64.

  161.  Antonarakis E, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.  The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: long-term follow-up.  BJU Intl 2012; 109:32-9.

  162.   Trock BJ.  Re:  Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease:  ND Arvold, MH Chen, JW Moul, BJ Moran, DE Dosoretz, LL Banez, MJ Katin, MH Braccioforte, AF D’Amico.  J Urol 2011; 186:91-96.  J Urol 2012; 187:356; author reply 356-7.

  163.  Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM.  Comparison of outcomes between pure laparoscopic vs. robot assisted laparoscopic radical prostatectomy:  a study of comparative effectiveness based upon validated quality of life outcomes.  BJU Int 2012; 109:898-905.

  164.  Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.  Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable risk prostate cancer.  BJU Int 2012; 110:651-7.

  165.  Epstein JI, Feng Z, Trock BJ, Pierorazio PM.  Upgrading and downgrading of prostate    cancer from biopsy to radical prostatectomy: incidence and predictive factors using the            modified Gleason grading system and factoring in tertiary grades.  Eur Urol 2012; 61:1019-24.

  166.   Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.  J Urol 2012; 188:1131-6.

  167.  Han M, Chang D, Kim C, Lee BJ, Zuo Y, Kim HJ, Petrisor D, Trock B, Partin AW, Rodriguez R, Carter HB, Allaf M, Stoianovici D.  Geometric evaluation of systematic transrectal ultrasound-guided prostate biopsy.  J Urol 2012; 188:2404-9.

  168.  Chalfin H, Feng Z, Dinizo M, Trock BJ, Partin AW, Walsh PC, Humphreys E, Han M.  Impact of surgical margin status on prostate cancer-specific mortality.  BJU Int 2012; 110:1684-9.

  169.   Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M.  Causes of death after radical prostatectomy at a large tertiary center.  J Urol 2012; 188:798-802.

  170.  Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R.  Active surveillance for low-risk prostate cancer.  Crit Rev Oncol Hematol 2012 Aug 6 [Epub ahead of print].

  171.  Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI.  Gleason score 6 adenocarcinoma: should it be labeled as “cancer”?  J Clin Oncol 2012; 30:4294-6.

  172.  Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R.  Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.  Clin Cancer Res 2012; 18:5471-8.

  173.   Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.  The impact of anatomical radical retropubic prostatectomy on cancer control:  the 30-year anniversary.  J Urol 2012; 188:2219-24.

  174.  Anusionwu I, Baradaran N, Trock BJ, Stec AA, Gearhart JP, Wright EJ.  Is pelvic osteotomy associated with lower risk of pelvic organ prolapse in postpubertal females with classic bladder exstrophy?  J Urol 2012; 188:2343-6.

  175.  Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock             BJ, Partin AW.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.  BJU Int 2013; 111:22-9.

  176.  Semins MJ, Feng Z, Trock B, Bohlman M, Hosek W, Matlaga BR.  Evaluation of acute renal colic: a comparison of non-contrast CT versus 3-T non-contrast HASTE MR urography.  Urolithiasis 2013; 41:43-6.

  177.   González-Roibón N, Han JS, Lee S, Feng Z, Arslankoz S, Smith N, Pierorazio PM, Humphreys E, Deweese TL, Partin AW, Bivalacqua TJ, Han M, Trock B, Netto GJ.  Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph        node metastases of prostate cancer.  Int J Surg Pathol 2013; 21:352-7.

  178.  Pierorazio PM, Hyams ES, Tsai S, Feng Z, Trock BJ, Mullins JK, Johnson PT, Fishman EK, Allaf ME.  Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma.  Urology 2013; 81:1265-71.

  179.  Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB.  Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.  J Urol 2013; 190:1218-22.

  180.  Sundi D, Reese AC, Mettee LZ, Trock BJ, Pavlovich CP.  Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men.  Urology 2013; 82:600-5.

  181.  Pavlovich CP, Levinson AW, Su LM, Mettee LZ, Feng Z, Bivalacqua TJ, Trock BJ. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo.  BJU Int 2013; 112:844-51.

  182.   Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ.  Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.  Prostate 2013; 73:1673-80.

  183.  Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.  Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.  J Urol. 2013 Sep 20. [Epub ahead of print]

  184.  Kaye DR, Hyndman ME, Segal RL, Mettee LZ, Trock BJ, Feng Z, Su LM, Bivalacqua TJ, Pavlovich CP.  Urology 2013; 82:1348-54.  Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy.

  185.  Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS.  Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network.  Prostate 2014; 74:61-9.

  186.  Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R.  Modeling grade progression in an active surveillance study.  Stat Med. 2013 Oct 9 [Epub ahead of print]

  187.   Kryvenko ON, Carter HB, Trock BJ, Epstein JI.  “Epstein criteria” for determining appropriateness for active surveillance in the modern era.  J Urol (in press).

  188.  Trock BJ.  Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.  Curr Opin Urol 2014; 24:293-302.

  189.   Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE.  Monitoring nanoparticle-mediated cellular hyperthermia with a high sensitivity biosensor.  Nanomedicine 2014; 9:2729-43.

  190.  Tan M, Shao C, Bishop JA, Feng Z, Trock BJ, Westra WH, Ha PK.  Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma.  Otolaryngol Head Neck Surg 2014 Feb 3 [Epub ahead of print].

  191.  Chalfin HJ, Frank SM, Feng Z, Trock BJ, Drake CG, Partin AW, Humphreys E, Ness PM, Jeong BC, Lee SB, Han M.  Allogeneic versus autologous blood transfusion and survival after radical prostatectomy.  Transfusion 2014 Mar 6 [Epub ahead of print].

  192.   Gorin MA, Chalfin HJ, Epstein JI, Feng Z, Partin AW, Trock BJ.  Predicting the risk of non- organ-confined prostate cancer when perineural invasion is found on biopsy.  Urology 2014; 83:1117-21.

  193.  Trock BJ.  Adjuvant radiation following radical prostatectomy:  what are the known unknowns?  Invited Editorial.  Eur Urol 2014; 66:251-2.

  194.   Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.  The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.  Eur Urol 2014 Jun 23 [Epub ahead of print].

  195.   Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer:  a comparison of the Johns Hopkins and PRIAS protocols.  BJU Int 2014 Jun [Epub ahead of print].

  196.   Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.  Obesity and long term survival after radical prostatectomy.  J Urol 2014; 192:1100-4.

  197.  Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.  J Urol 2014; 192:1081-7.

  198.  Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB. Fluoroquinolone resistance in the rectal carriage of en in an active surveillance cohort: longitudinal analysis.  J Urol. 2015; 193:552-6.

  199.   Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy:  estimates based on patient and tumor characteristics.  Clin Cancer Res. 2014; 20:5302-10.

  200.  Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI, Trock BJ, Macura KJ.  Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.  Urology. 2015; 85:147-53.

  201.   Trock BJ.  Editorial Comment on:  “Bhindi B, Margel D, Hamilton RJ, et al.  The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy.  Urology 2014; 84:1073-8.”  Urology 2014; 84:1079.

  202.  Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM.  Reclassification rates are higher among African American men than Caucasians on active surveillance.  Urology 2015; 85:155-60.

  203.  Patel HD, Trock BJ, Han M, Carter HB.  Practice patterns and individual variability of surgeons performing radical prostatectomies at a high volume academic center.  J Urol 2015; 193:812-19.

  204.   Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg R.  Nanowire analysis of cancer/testis antigens (CTAs) as biomarkers of aggressive prostate cancer.  Urology 2015; 85:704.e1-7.

  205.   Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ.  Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?  Cancer 2015; 121:1414-21.

  206.   Ko JS, Chalfin H, Trock BJ, Feng Z, Humphreys E, Park SW, Carter HB, Frick KD, Han M.  Variability in Medicare utilization and payment among urologists.  Urology 2015; 85:1045-50.

  207.   Pierorazio PM,  Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: The DISSRM Registry.  Eur Urol 2015; 68:408-15.

  208.   Ball MW,  Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio PM, Allaf ME.  Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: A multi-institutional analysis.  Urol Oncol 2015; 33:112.e9-112.e14.

  209.  Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM.  Utility of risk models in decision making after radical prostatectomy: lessons from a natural history cohort of intermediate- and high-risk men.  Eur Urol 2015 Apr 25 [Epub ahead of print].

  210.   Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.  Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.  Eur Urol 2015 Oct;68(4):555-67.

  211.  Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men.  Eur Urol 2016; 69:157-65.

  212.   Malmström PU, Trock BJRe: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pta-pt1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol In press.  Eur Urol 2016; 69:e10-1.

  213.  Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer.  J Clin Oncol 2015; 33:3379-85.

  214.   Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Predictors of adverse pathology in men undergoing radical prostatectomy following initial active surveillance.  Urology 2015; 86:991-7.

  215.  Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M. Pathologic outcomes in favorable-risk prostate cancer: comparative analysis of men electing active surveillance and immediate surgery.  Eur Urol 2015 Oct 5 [EPub ahead of Print].

  216.   Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. Clinical validation of the 2005 ISUP Gleason grading system in a cohort of intermediate and high risk men undergoing radical prostatectomy.  PLoS One 2016;11:e0146189

Book Chapters:

  1. Trock BJ:  Application of a mathematical carcinogenesis model to chemoprevention.  In Biomedical Modeling and Simulation.  J Eisenfeld, DS Levine (Eds.), JC Baltzer, AG Scientific Publishing Co., 1989, pps. 43-45.
  2. Lanza E, Shankar S, Trock B:  Dietary Fiber.  In Macronutrients:  Investigating Their Role in Cancer, Micozzi MS, Moon TE (Eds.), Marcel Dekker, Inc., New York, 1992.
  3. Engstrom PF, Trock B, Rimer BK:  Prevention of tobacco-related cancer.  In Cancer Medicine, 3rd Edition, Lea and Febiger, Philadelphia, 1993, pps. 361-370.
  4. Trock BJ.  Dietary fiber: Defining criteria for labeling and health messages based on the scientific evidence.  In America's Foods Health Messages and Claims:  Scientific, Regulatory and Legal Issues, Tillotson JE (Ed), CRC Press, Ann Arbor, 1993, pps. 141-153.
  5. Trock BJ.  Molecular epidemiology.  In:  Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds.).  JB Lippincott Co., Philadelphia, 1995, pps. 213-220.
  6. Hilakivi-Clarke L, Trock BJ, Clarke R.  The estrogenicity of selected nutrients, phytochemicals, pesticides and pollutants: their potential roles in breast cancer.  In:  Contemporary Cancer Research:   Breast Cancer:   molecular genetics, pathogenesis and therapeutics.   Bowcock AM (Ed.).  Humana Press, Totowa NJ. 1999, pps. 537-567.
  7. Grossman L, Matanoski G, Farmer E, Hedyati M, Ray S, Trock BJ, Hanfelt J, et al.  DNA repair as a susceptibility factor in chronic diseases in human populations.  In:  Advances in DNA Damage and Repair.  Dizdaroglu, Karakaya (Eds.). Kluwer Academic/Plenum Pubs., NY, 1999, pps. 149-167.
  8. Kerner JF, Trock BJ, Mandelblatt JS.  Breast cancer in minority women.  In:  Diseases of the Breast, 2nd Ed.  Harris JR, Lippman ME, Morrow M, Osborne CK (Eds.).  Lippincott Williams and Wilkins, Baltimore, 2000, pps. 955-966.
  9. Kerner JF, Trock BJ, Mandelblatt JS.  Breast cancer in minority women.  In:  Diseases of the Breast, 3rd Ed.  Harris JR, Lippman ME, Morrow M, Osborne CK (Eds.).  Lippincott Williams and Wilkins, Baltimore, 2004, pps. 1351-1364. 
  10. Trock BJ.  Applications of gene array technology in prostate cancer.  In:  Prostate Cancer:  Principles and Practice.    Kirby R, Partin A, Feneley M, Parsons JK (Eds.).  Taylor and Francis, New York, 2006.




  • Society for Epidemiologic Research

  • American Society of Preventive Oncology

  • American Association for Cancer Research

Awards & Honors

7/1/01-6/30/02 Principal Investigator. Impact of Environmental Cadmium Exposure on Prostate Cancer Risk in the Baltimore Metropolitan Area. Maryland Cigarette Restitution Fund
10/1/99-9/30/04 Principal Investigator. Detecting Breast Cancer Protein Signatures in Body Fluids. National Cancer Institute
10/1/99-9/30/02 Principal Investigator. Molecular Epidemiology of Prostate Cancer. Department of Defense
7/1/98-6/30/01 Principal Investigator. Angiogenic growth factors in nipple aspirate fluid. Department of Defense
1996-1999 Principal Investigator. Role of Cadmium in the Development of Breast Cancer. American Cancer Society
1993-1996 Principal Investigator. Molecular Epidemiology of Head and Neck Cancer. American Cancer Society
1995- 2000 Principal Investigator. Breast Cancer Serum Bank Core Facility - SPORE in Breast Cancer. National Cancer Institute
1996-1997 Principal Investigator. Early Detection Based on p53 in Nipple Aspirate Fluid. Cancer Research Foundation of American
1996-2000 Co-Principal Investigator. A Coordinated Approach to Breast Cancer Diagnosis. Department of Defense